胸腺肽α1治疗急性乙型病毒性肝炎的临床意义  

Clinical Significance of Thymosin-α1 Therapy for Acute Viral Hepatitis B

作　　者：王会清[1,2] 于爱平[1] 刘钰佩[2] 段毅力[2] 曹武奎[2] 

机构地区：[1]天津医科大学研究生院,300070 [2]天津市传染病医院

出　　处：《天津医药》2010年第5期375-377,共3页Tianjin Medical Journal

摘　　要：目的:观察胸腺肽α1治疗急性乙型病毒性肝炎的治疗效果。方法:将62例急性乙型病毒性肝炎患者分为治疗组42例(护肝治疗+胸腺肽α1)和对照组(护肝治疗)20例,检测治疗前、治疗后2、4、6周肝功能、乙肝表面抗原(HBsAg)、乙肝e抗原(HBeAg)及HBV DNA定量等指标,比较2组在各个时期的恢复率。结果:治疗4周时治疗组HBeAg转阴率和HBV DNA转阴率与对照组比较差异有统计学意义(P<0.05);治疗6周时治疗组HBsAg转阴率和HBV DNA转阴率与对照组比较差异有统计学意义(P<0.05或P<0.01)。治疗组与对照组在肝功能恢复方面比较差异无统计学意义(P>0.05)。未发现胸腺肽α1有关的不良反应。结论:胸腺肽α1能加快急性乙型病毒性肝炎乙肝病毒标志物的清除,缩短患者恢复时间,减少急性乙型病毒性肝炎慢性化的发生。Objective： To observe the efficacy of the thymosin-α1 therapy for acute viral hepatitis B.Methods： Six-two cases of acute viral hepatitis B were divided into the treatment group （n = 42,liver treatment ＋ thymosin-α1） and the control group （n = 20,liver treatment）.The patients were observed for 6 weeks.The liver function,hepatitis B surface antigen （HBsAg）,hepatitis B e antigen（HBeAg）,HBV DNA and other indicators were detected before and after treatment for 2,4,6 weeks to compare the recovery rates of the two groups at different times.Results： After 4 weeks treatment,the HBeAg-seroconversion rate and HBV DNA -negative conversion rate were significantly higher in treatment group than those in control group （P 0.05）.After 6 weeks treatment,HBsAg-negative conversion rate and HBV DNA-negative conversion rate were significantly different between the treatment group and the control group （P 0.05 or P 0.01）.There was no significant difference in the liver function recovery between the treatment group and control group.No side effects were observed in patients given thymosin-α1.Conclusion： Thymosin-α1 accelerated the clearing of hepatitis B markers,shorter the recovery time of patients,reduced the occurrence of chronic hepatitis B.

关 键 词：胸腺素 肝炎 乙型 肝炎表面抗原 乙型 临床方案 治疗结果 

分 类 号：R512.62[医药卫生—内科学]